Floatz logo

Mitoxantrone

Neoantigen

BGI, ChinaSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Neoantigen cohort.

Asset / SponsorPhaseRating
Targeted Aml1-Eto Neoantigen Cytotoxic T Cells
BGI, China
Early Phase 1C
Decitabine
BGI, China
Early Phase 1C
Cyclophosphamide
BGI, China
Early Phase 1C

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →